Low-grade gliomas: an update on pathology and therapy
暂无分享,去创建一个
[1] A. Tolcher,et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules , 2003, British Journal of Cancer.
[2] B. Fisher,et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. , 1999, International journal of radiation oncology, biology, physics.
[3] Jean-Yves Delattre,et al. OLIG2 as a specific marker of oligodendroglial tumour cells , 2001, The Lancet.
[4] B. Fisher,et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] I. R. Williams,et al. The prognosis of primary intracerebral tumours presenting with epilepsy: the outcome of medical and surgical management. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[6] J. Hunter,et al. Late cognitive and radiographic changes related to radiotherapy: Initial prospective findings , 2002, Neurology.
[7] D. Figarella-Branger,et al. Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. , 2003, Journal of neurosurgery.
[8] R. Morantz. Radiation Therapy in the Treatment of Cerebral Astrocytoma , 1987, Neurosurgery.
[9] G. Reifenberger,et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. , 1994, The American journal of pathology.
[10] J. Jolles,et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study , 2002, The Lancet.
[11] J. Henson,et al. Age-dependent rate of anaplastic transformation in low-grade astrocytoma , 1999, Neurology.
[12] D. Rowitch,et al. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[13] I. Diamantis,et al. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material , 2004, Acta Neuropathologica.
[14] J. Delattre,et al. Neurological complications of radiotherapy and chemotherapy , 1998, Journal of Neurology.
[15] L. Deangelis,et al. Long-term outcome of low-grade oligodendroglioma and mixed glioma , 2000, Neurology.
[16] H. Budka,et al. Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: Gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendroglioma , 2004, Acta Neuropathologica.
[17] A. Paetau,et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients , 2001, Neurology.
[18] B. Scheithauer,et al. Clinical Utility of Fluorescence In Situ Hybridization (FISH) in Morphologically Ambiguous Gliomas with Hybrid Oligodendroglial/Astrocytic Features , 2003, Journal of neuropathology and experimental neurology.
[19] D. Louis,et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.
[20] C. Daumas-Duport,et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. , 1989, Journal of neurosurgery.
[21] J. Knisely,et al. Early vs. delayed radiotherapy in a small cohort of patients with supratentorial low grade glioma , 1997, Journal of Neuro-Oncology.
[22] Arie Perry,et al. Pathology of low-grade gliomas: an update of emerging concepts. , 2003, Neuro-oncology.
[23] J. Cairncross,et al. Successful chemotherapy for recurrent malignant oligodendroglioma , 1988, Annals of neurology.
[24] A. Aguzzi,et al. Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice , 1997, Oncogene.
[25] David J Anderson,et al. Identification of a Novel Family of Oligodendrocyte Lineage-Specific Basic Helix–Loop–Helix Transcription Factors , 2000, Neuron.
[26] I. Whittle,et al. Seizures in patients with supratentorial oligodendroglial tumours , 2006, Acta Neurochirurgica.
[27] J. Menten,et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] T. Montine,et al. Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. , 1994, Neurosurgery.
[29] Y. Shibamoto,et al. Supratentorial low‐grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables , 1993, Cancer.
[30] D. Troost,et al. 5-Year survival and clinical prognostic factors in progressive supratentorial diffuse “low-grade” astrocytoma: A retrospective analysis of 46 cases , 2005, Acta Neurochirurgica.
[31] Melissa Bondy,et al. Epidemiology of primary brain tumors: current concepts and review of the literature. , 2002, Neuro-oncology.
[32] W. Huk,et al. Supratentorial Low-Grade Glioma: Results and Prognostic Factors Following Postoperative Radiotherapy , 1999, Strahlentherapie und Onkologie.
[33] M. Taphoorn,et al. Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas , 2001, Neurology.
[34] K. Skullerud,et al. Prevalence and prognostic significance of epilepsy in patients with gliomas. , 1998, European journal of cancer.
[35] M. Strawderman,et al. MIB-1 Proliferation Index Predicts Survival among Patients with Grade II Astrocytoma , 1998, Journal of neuropathology and experimental neurology.
[36] Y. Yonekawa,et al. Role of gemistocytes in astrocytoma progression. , 1997, Laboratory investigation; a journal of technical methods and pathology.
[37] C. Fuller,et al. Fluorescence In Situ Hybridization (FISH) in Diagnostic and Investigative Neuropathology , 2002, Brain pathology.
[38] G. Fuller,et al. Genetic Modeling of Glioma Formation in Mice , 2002, Brain pathology.
[39] Karlyne M. Reilly,et al. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum , 2002, Oncogene.
[40] M. Faist,et al. Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas , 1997, Cancer.
[41] D. Nelson,et al. White matter changes are correlated significantly with radiation dose. Observations from a randomized dose‐escalation trial for malignant glioma (radiation therapy oncology group 83‐02) , 1994, Cancer.
[42] M. Berger,et al. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas , 1994, Cancer.
[43] I. Fried,et al. Low-grade astrocytomas may arise from different astrocyte lineages. , 1993, Neurosurgery.
[44] J. Burbach,et al. Somatic mutations in the brain: relationship to aging? , 1995, Mutation research.
[45] P. Scheltens,et al. Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma , 2002, Neurology.
[46] S. Kollias,et al. Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme , 2004, Journal of Neuro-Oncology.
[47] Allan H Friedman,et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Robert B. Jenkins,et al. Losses of Chromosomal Arms 1p and 19q in the Diagnosis of Oligodendroglioma. A Study of Paraffin-Embedded Sections , 2001, Modern Pathology.
[49] G. Barnett,et al. Impact of Chromosome 1p Status in Response of Oligodendroglioma to Temozolomide: Preliminary Results , 2003, Journal of Neuro-Oncology.
[50] G. Broggi,et al. Low-grade glial tumors in basal ganglia and thalamus: natural history and biological reappraisal. , 1994, Neurosurgery.
[51] D. Louis,et al. Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma , 1995, Journal of neuropathology and experimental neurology.
[52] Y. Yonekawa,et al. p14ARF Deletion and Methylation in Genetic Pathways to Glioblastomas , 2001, Brain pathology.
[53] H. Kurzen,et al. Inhibition of angiogenesis by non-toxic doses of temozolomide , 2003, Anti-cancer drugs.
[54] M. Taphoorn,et al. Delayed Radiation Toxicity after Focal or Whole Brain Radiotherapy for Low-Grade Glioma , 2004, Journal of Neuro-Oncology.
[55] Susan M. Chang,et al. Age and the risk of anaplasia in magnetic resonance‐nonenhancing supratentorial cerebral tumors , 1997, Cancer.
[56] J. Villemure,et al. Low-grade pure and mixed cerebral astrocytomas treated in the CT scan era , 1996, Journal of Neuro-Oncology.
[57] D. Spencer,et al. Low-grade gliomas of chronic epilepsy: A distinct clinical and pathological entity , 1997, Journal of Neuro-Oncology.
[58] R. Makuch,et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. , 1996, Neurosurgery.
[59] P. Kleihues,et al. p53 mutations in nonastrocytic human brain tumors. , 1991, Cancer research.
[60] T. H. van der Kwast,et al. Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas , 1990, Cancer.
[61] D. Gutmann,et al. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. , 2001, Cancer research.
[62] A. Karim,et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. , 1996, International journal of radiation oncology, biology, physics.
[63] W F Taylor,et al. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. , 1984, Journal of neurosurgery.
[64] K. Fulling,et al. The value of radiation therapy in addition to surgery for astrocytomas of the adult cerebrum , 1985, Cancer.
[65] B. Scheithauer,et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] B A Kall,et al. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. , 1987, Mayo Clinic proceedings.
[67] K. Hoang-Xuan,et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] K Takakura,et al. Subacute brain atrophy after radiation therapy for malignant brain tumor , 1989, Cancer.
[69] M. Strawderman,et al. Proliferation index is related to patient age in glioblastoma , 2001, Neurology.
[70] David N Louis,et al. Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro‐Oncology , 2003, Journal of neuropathology and experimental neurology.
[71] A. Gregor,et al. Radiotherapy for malignant glioma , 1996, BMJ.
[72] Laurent Capelle,et al. Preferential brain locations of low‐grade gliomas , 2004, Cancer.
[73] M. Prados,et al. Gemistocytic astrocytomas: a reappraisal. , 1991, Journal of neurosurgery.
[74] A. Bricolo,et al. Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adult patients. , 1995, Surgical neurology.
[75] S. Ashley,et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[76] V. Levin,et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] L D Lunsford,et al. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. , 1993, Journal of neurosurgery.
[78] L. Recht,et al. Suspected low‐grade glioma: Is deferring treatment safe? , 1992, Annals of neurology.
[79] B. Scheithauer,et al. Cellular proliferation in pilocytic and diffuse astrocytomas. , 1999, Journal of neuropathology and experimental neurology.
[80] S. Clemenceau,et al. Supratentorial low-grade astrocytomas in adults. , 1993, Neurosurgery.
[81] M. Middleton,et al. Temozolomide: a novel oral alkylating agent , 2001, Expert review of anticancer therapy.
[82] B. Scheithauer,et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] A. Twijnstra,et al. Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2 , 2002, Genes, chromosomes & cancer.
[84] C. Duyckaerts,et al. Dementia Following Treatment of Brain Tumors with Radiotherapy Administered Alone or in Combination with Nitrosourea-based Chemotherapy: A Clinical and Pathological Study , 2004, Journal of Neuro-Oncology.
[85] D. Kondziolka,et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients , 2001, Neurology.
[86] D. Louis,et al. Molecular Genetic Evidence for Subtypes of Oligoastrocytomas , 1997, Journal of neuropathology and experimental neurology.
[87] T E Schultheiss,et al. Radiation response of the central nervous system. , 1995, International journal of radiation oncology, biology, physics.
[88] M. Berger,et al. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. , 2001, Journal of neurosurgery.
[89] B. Scheithauer,et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[91] R. Soffietti,et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. , 1998, Neurosurgery.
[92] B. Jeremic,et al. Radiation Therapy for Incompletely Resected Supratentorial Low-grade Glioma in Adults , 2001, Journal of Neuro-Oncology.
[93] D K Pearl,et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas , 1997, Cancer.
[94] J. Delattre,et al. A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. , 1996, International journal of radiation oncology, biology, physics.
[95] G. Krol,et al. Low-grade oligodendroglioma responds to chemotherapy , 1996, Neurology.
[96] H. Morris,et al. Coexistence of Neoplasia and Cortical Dysplasia in Patients Presenting with Seizures , 1993, Epilepsia.
[97] A. Cianciulli,et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[98] Catherine L Nutt,et al. The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse Gliomas , 2004, Journal of neuropathology and experimental neurology.
[99] Philippe Cornu,et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. , 2002, International journal of radiation oncology, biology, physics.
[100] C. Avezaat,et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery , 1998, Journal of neurology, neurosurgery, and psychiatry.
[101] M. Selch,et al. Management of oligodendrogliomas. , 1993, Radiology.
[102] Desmond Curran,et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised Phase III trial on dose response (EORTC trial 22844) , 1998 .
[103] S B Green,et al. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] R. Gonzalez,et al. MRI in treatment of adult gliomas. , 2005, The Lancet. Oncology.
[105] M. J. van den Bent,et al. Successful treatment of low‐grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine , 2005, Cancer.
[106] A. Karim,et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[107] K. Hoang-Xuan,et al. OLIG‐1 and 2 gene expression and oligodendroglial tumours , 2002, Neuropathology and applied neurobiology.
[108] M. J. van den Bent,et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[109] S. Coons,et al. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. , 1997, Neurosurgery.
[110] Joanne Chan,et al. Sonic Hedgehog–Regulated Oligodendrocyte Lineage Genes Encoding bHLH Proteins in the Mammalian Central Nervous System , 2000, Neuron.
[111] G. Fuller,et al. Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. , 2000, The American journal of pathology.
[112] D. Louis,et al. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. , 2001, Genes & development.